Skip to content

Non-recessive randomized controlled trial under OLED illumination - Randomized crossover controlled trial

Non-recessive randomized controlled trial under OLED illumination - Randomized crossover controlled trial - Non-recessive randomized controlled trial under OLED illumination - Randomized crossover controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000047445
Enrollment
35
Registered
2022-04-09
Start date
2022-04-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subject

Interventions

irradiate for 30 minutes (at rest), rest for 5 minutes, and irradiate for 120 minutes (at work) under the study lighting environment, respectively. irradiate for 30 minutes (at rest), rest for 5 minut

Sponsors

Mibyou Life Science Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Japanese men and women between 20 and 50 years old at the time of obtaining consent 2) Healthy people who have not received any treatment 3) Designated visits, items that can fill in records 4) Those with general computing power 5) With a normal sleep of 7 hours or more 6) Those who have received sufficient explanations about the purpose and content of the examination and agree to participate in writing at will

Exclusion criteria

Exclusion criteria: 1) Visual abnormalities *Colorblind, color weakness or eye disease 2) Lasik surgery/ Glasses, eye vision correction with contact lenses 3) Pregnant and lactating 4) Irregular lifestyle habits 5) Drinking more than 20 g per day 6) With more than 20 smoking per day 7) Foods for specified health use, foods with functional indications, and other foods that cannot be refrained from consuming so-called health foods during the study period 8) Participation in other clinical trials or clinical trials within the last month

Design outcomes

Primary

MeasureTime frame
Uchida-Kraepelin test(average number of answer)

Secondary

MeasureTime frame
average number of error, Karolinska sleepiness scale, KSS

Countries

Japan

Contacts

Public ContactSoichi Yoneda

Mibyou Life Science Inc. Clinical Trial Division

renraku@mibyou-ls.com03-6256-9600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026